LivaNova PLC (NASDAQ:LIVN) Given Average Recommendation of “Moderate Buy” by Brokerages

LivaNova PLC (NASDAQ:LIVN) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $69.3750.

A number of equities research analysts have commented on LIVN shares. Mizuho raised their price objective on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Weiss Ratings restated a “sell (d+)” rating on shares of LivaNova in a research note on Monday, December 29th. Robert W. Baird set a $75.00 price objective on shares of LivaNova in a research note on Tuesday, December 16th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $66.00 price objective on shares of LivaNova in a report on Friday, January 9th.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. New York State Common Retirement Fund grew its position in shares of LivaNova by 79.6% during the 2nd quarter. New York State Common Retirement Fund now owns 86,741 shares of the company’s stock valued at $3,905,000 after acquiring an additional 38,451 shares during the period. Emerald Mutual Fund Advisers Trust lifted its stake in LivaNova by 8.1% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 349,664 shares of the company’s stock valued at $18,315,000 after purchasing an additional 26,202 shares during the last quarter. Aberdeen Group plc grew its holdings in LivaNova by 18.1% during the second quarter. Aberdeen Group plc now owns 326,786 shares of the company’s stock valued at $14,712,000 after purchasing an additional 50,076 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in LivaNova during the second quarter valued at $1,713,000. Finally, Quantbot Technologies LP purchased a new stake in LivaNova in the second quarter worth $1,378,000. 97.64% of the stock is owned by institutional investors.

LivaNova Stock Performance

Shares of LivaNova stock opened at $65.71 on Friday. The business has a 50-day simple moving average of $63.09 and a 200 day simple moving average of $55.92. LivaNova has a one year low of $32.48 and a one year high of $65.95. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12. The firm has a market capitalization of $3.59 billion, a price-to-earnings ratio of -16.43 and a beta of 0.97.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.